Ali Health's stock plummeted 5.07% during intraday trading on Tuesday, reflecting significant selling pressure in the medical e-commerce sector.
The decline was driven by broad weakness in the medical e-commerce sector for a second consecutive session, with peers JD Health and PA Good Doctor also falling sharply. Additionally, UBS maintained its sell rating on Ali Health and lowered its target price to HK$3.1, with the current share price converging toward this bearish target.
Persistent institutional outflows further weighed on sentiment, as southbound capital cumulatively net sold over 128 million shares over the past 20 trading days. Despite Ali Health reporting robust FY2026 results with revenue growth of 12% and net profit growth of 35.2%, bearish analyst positioning and weak capital flows dominated near-term price action.
Comments